Pr ecis: Colorectal cancer patients whose tumors harbor unstable DNA microsatellite repeats, representing about $15% of all cases of colorectal cancers, express frameshift mutation-derived neoantigens, constituting a special opportunity for developing new personalized immunotherapy strategies.
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AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis
Weidong Ji, Yonghao Li, Yun He, Mingzhu Yin, Huanjiao Jenny Zhou, Titus J. Boggon, Haifeng Zhang, and Wang Min Pr ecis: Expression of the suppressor gene AIP1 in the microenvironment of a premetastatic niche is found to suppress EMT, angiogenesis, and metastatic progression, illustrating a role for tumor suppression genes not only in tumor cells but also stromal cells of the tumor microenvironment. Pr ecis: This study addresses the lack of effective targeted therapeutic options for BRAF/NRAS wild-type melanomas, offering a preclinical basis for new treatment strategies in a subset of these melanomas.
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Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy Yi-Ta Tsai, Mei-Jen Chuang, Shou-Hung Tang, Sheng-Tang Wu, Yu-Chi Chen, Guang-Huan Sun, Pei-Wen Hsiao, Shih-Ming Huang, Hwei-Jen Lee, Cheng-Ping Yu, Jar-Yi Ho, Hui-Kuan Lin, Ming-Rong Chen, Chung-Chih Lin, Sun-Yran Chang, Victor C. Lin, Dah-Shyong Yu, and Tai-Lung Cha Pr ecis: These findings suggest a novel predictive biomarker for responses to combination therapy with Raf kinase inhibitors, which have a variety of antimetabolic and immune modulatory effects beyond the inhibition of growth and survival in cancer cells. Pr ecis: These results provide a preclinical rationale to target IL6 or its downstream effector functions as a novel therapeutic option in endometrial cancer, with immediate potential implications for a clinical evaluation of IL6-blocking antibodies or JAK inhibitors in this setting.
Pr ecis: This important study establishes that keratin-17 functions specially among keratins as an oncoprotein by controlling the ability of the tumor suppressor p27KIP1 to influence cervical cancer pathogenesis.
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Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
Duo Xu, Yang Zhan, Yanfeng Qi, Bo Cao, Shanshan Bai, Wei Xu, Sanjiv S. Gambhir, Peng Lee, Oliver Sartor, Erik K. Flemington, Haitao Zhang, Chang-Deng Hu, and Yan Dong Pr ecis: These results clarify how variant splice forms of the androgen receptor function to drive the malignant character of advanced prostate cancer, providing key mechanistic insights that will promote rational drug design for more effective treatment of this deadly disease. 
ABOUT THE COVER
Combination immunotherapy with anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab) monoclonal antibodies (mAb) in a humanized mouse model enhances the human T-cell infiltrate in xenografted tumors. Using multiplexed quantitative immunofluorescence, we profiled T-and B-cells in the tumor microenvironment. In immunodeficient Rag2 À/À IL2Rg null mice subcutaneously bearing human gastric carcinoma and transferred with peripheral blood mononuclear cells from the same patient, urelumab and nivolumab increased the T-cell infiltrates that were penetrating into the tumor. The presence of T lymphocytes was associated with slow tumor progression. In contrast, tumor-infiltrating lymphocytes (TIL) were restricted to the tumor periphery when treatment consisted of control hIgG4 mAb or either urelumab or nivolumab as single agents. The combination of urelumab and nivolumab seems to help overcome a peripheral barrier so TILs can enter the tumor core. For details, see article by Sanmamed and colleagues on page 3466. 
